Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.
After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...
Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.
Zacks Investment Research on MSN
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback